Webinar

Improving Clinical Diagnostic Practice in FOLR1 Testing for Ovarian Cancer

Available on-demand

60 Minutes

Folate Receptor alpha (FRα) is expressed in 90% of ovarian cancers and has limited expression in normal tissue, making it an actionable therapeutic target in platinum-resistant ovarian cancer. It is therefore critical that all ovarian cancer patients now be tested for FRα expression.

Join us for this webinar to take a deep dive into FOLR1 testing for ovarian cancer. Discover how to reduce barriers to immunohistochemistry (IHC) testing for novel biomarkers and make informed treatment decisions for patients.

In this important discussion, industry experts will explore:

Key insights on the FOLR1 biomarker
How FRa expression is determined utilizing IHC testing vs. genomic testing
The latest therapies, clinical trial results and FDA approvals
Details regarding sponsored testing programs (STP) for FOLR1
And more

Speakers

Thomas C. Krivak, MD

Oncologist; Director of the Ovarian Cancer Center of Excellence

Allegheny Health Network (AHN)

Thomas Krivak, MD is the director of the Ovarian Cancer Center of Excellence and co-chair of the Society of Gynecologic Oncology Research Institute. He specializes in treating ovarian, uterine and other gynecologic cancers and has particular expertise in minimally invasive surgical techniques, as well as non-invasive options.

Register here to watch on-demand!

Already registered? Click here to login.

Duration:

60 Minutes